<font color="red">Systemic_1</font> <font color="red">hemodynamic_1</font> <font color="red">,_1</font> <font color="red">neurohormonal_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">renal_1</font> <font color="red">effects_1</font> of a steady - state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure . 
<br>
<br> BACKGROUND Human brain natriuretic peptide ( hBNP ) is a promising agent for the treatment of decompensated cardiac failure . However , the <font color="red">systemic_1</font> <font color="red">hemodynamic_1</font> <font color="red">,_1</font> <font color="red">neurohormonal_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">renal_1</font> <font color="red">effects_1</font> of hBNP have been incompletely studied in human heart failure . 
<br> METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in 16 decompensated heart failure patients in an invasive , randomized , double - blind , placebo - controlled study . Patients were evaluated during three 4-hour study periods : baseline , treatment ( placebo [ n = 4 ] versus hBNP 0.025 or 0.05 microgram / kg / min [ n = 12 ] ) , and post - treatment . Urinary volume losses were replaced hourly to separate the vasodilatory and diuretic effects of hBNP . Two patients in the hBNP group were excluded from the analysis because of <font color="red">adverse_1</font> <font color="red">events_1</font> <font color="red">._1</font> hBNP significantly ( P < .001 ) reduced <font color="red">right_1</font> <font color="red">atrial_1</font> <font color="red">pressure_1</font> and <font color="red">pulmonary_1</font> <font color="red">capillary_1</font> <font color="red">wedge_1</font> <font color="red">pressure_1</font> by approximately 30% and 40% , respectively . hBNP also significantly lowered <font color="red">systemic_1</font> <font color="red">vascular_1</font> <font color="red">resistance_1</font> from 1722 + /- 139 to 1101 + /- 83 dynes.s.cm-5 ( P < .05 ) . These unloading effects of hBNP produced a 28% increase in <font color="red">cardiac_1</font> <font color="red">index_1</font> ( P < .05 ) with no change in <font color="red">heart_1</font> <font color="red">rate_1</font> <font color="red">._1</font> Compared to placebo , hBNP decreased <font color="red">plasma_1</font> <font color="red">norepinephrine_1</font> <font color="red">and_1</font> <font color="red">aldosterone_1</font> <font color="red">._1</font> <font color="red">Renal_1</font> <font color="red">hemodynamics_1</font> were unaffected by hBNP ; however , most patients were resistant to its <font color="red">natriuretic_1</font> <font color="red">effect_1</font> <font color="red">._1</font> 
<br> CONCLUSIONS 1 ) The predominant <font color="red">hemodynamic_1</font> <font color="red">effects_1</font> of hBNP were a decrease in <font color="red">cardiac_1</font> <font color="red">preload_1</font> and <font color="red">systemic_1</font> <font color="red">vascular_1</font> <font color="red">resistance_1</font> <font color="red">._1</font> 2 ) hBNP also improved <font color="red">cardiac_1</font> <font color="red">output_1</font> without increasing <font color="red">heart_1</font> <font color="red">rate_1</font> <font color="red">._1</font> 3 ) <font color="red">Plasma_1</font> <font color="red">norepinephrine_1</font> <font color="red">and_1</font> <font color="red">aldosterone_1</font> <font color="red">levels_1</font> decreased during hBNP infusion . 4 ) hBNP is pharmacologically active and has potential in the therapy for decompensated heart failure .